Acumen Pharmaceuticals, Inc. — Director's Dealing 2021

Jul 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Acumen Pharmaceuticals, Inc. (ABOS)
CIK: 0001576885
Period of Report: 2021-07-06

Reporting Person: Zuga Matt (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-06	Common Stock	C	26187	—	Acquired	26187	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-06	Series A-1 Preferred Stock	$	C	15659	Disposed		Common Stock (15659)	Direct
2021-07-06	Series B Preferred Stock	$	C	10528	Disposed		Common Stock (10528)	Direct

Footnotes

F1: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred
Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of
the Issuer's common stock. The shares had no expiration date.